Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Biostimulators and energy-based devices are increasingly used in combination to address visible signs of aging. Previous research demonstrated that pairing microfocused ultrasound with visualization (MFU-V) and hyperdiluted calcium hydroxylapatite-carboxymethylcellulose (CaHA-CMC) enhances dermal elastin synthesis and improves aesthetic outcomes up to 120 days posttreatment. However, the impact of patient age on the histological response to these treatments remains unclear.
Objectives: To explore whether age influences the biostimulatory response to combined hyperdiluted CaHA-CMC and MFU-V treatments in healthy adults aged 39 to 62 years.
Methods: This secondary analysis leveraged data from a 12-patient, IRB-approved clinical study in which patients received 2 combination treatment protocols: Group A (MFU-V followed by hyperdiluted CaHA-CMC) and Group B (hyperdiluted CaHA-CMC followed by MFU-V). Biopsies obtained before and 120 days after completion of treatments were stained for elastin and quantitatively assessed. Linear regression analyses assessed correlations between age and changes in elastin staining intensity and area coverage.
Results: No significant correlation was found between patient age and changes in dermal elastin intensity or area. In subgroup analyses, neither protocol showed a significant age-dependent difference in elastin intensity. Although 1 subgroup (Group B) revealed a marginal correlation between age and elastin area, the pooled data did not support age as a significant predictor of biostimulatory response.
Conclusions: This exploratory analysis suggests that within the studied age range, patient age may not significantly influence the histological response to combined CaHA-CMC and MFU-V treatments. Larger, statistically powered studies are needed to validate these findings and further investigate age-related effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062575 | PMC |
| http://dx.doi.org/10.1093/asjof/ojaf023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Progesterone-induced activation of progesterone receptor alleviates alveolar bone resorption and inflammatory response in periodontitis.
Clin Oral Investig
September 2025
Department of Stomatology, Shengli Oilfield Central Hospital, No. 31, Jinan Road, Dongying, 257034, China.
Objective: Progesterone (PG) and its target, progesterone receptor (PGR), are important regulators in inflammatory diseases. This study aimed to investigate the specific role of PG in periodontitis and to elucidate the underlying mechanisms involving PGR.
Methods: Women with periodontitis, including 250 with PG deficiency, 250 with PG supplementation, and 245 controls (normal PG) were enrolled.
MRI-based radiomics signatures for predicting the efficacy of targeted therapy with lenvatinib in hepatocellular carcinoma: a retrospective cohort study.
J Cancer Res Clin Oncol
September 2025
Department of Radiology, Guizhou Provincial People's Hospital, No. 83 East Zhongshan Road, Guiyang, 550002, Guizhou, China.
Purpose: Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.
Methods: This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients).
Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.
Cancer Immunol Immunother
September 2025
Department of Gastric Surgery, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Hangzhou, 310022, Zhejiang, China.
Objectives: To evaluate the efficacy of combining PD-1 inhibitors with chemotherapy in conversion therapy for patients with stage IV gastric cancer and to determine the populations most likely to benefit from this regimen.
Methods: Data from patients with stage IV gastric cancer who received conversion therapy with PD-1 inhibitors combined with chemotherapy between January 2018 and December 2022 at multiple centers were retrospectively reviewed. Patients who underwent conversion surgery were categorized into a surgery group, while those who did not were placed into a palliative group.
The STING/type I interferon axis drives the interplay between marginal zone B cells and T follicular helper cells in Sjögren's disease.
Cell Mol Immunol
September 2025
School of Chinese Medicine, the University of Hong Kong, Hong Kong SAR, China.
Type I interferon (IFN-I) is highly prevalent in autoimmune disorders and is intricately involved in disease pathogenesis, including Sjögren's disease (SjD), also known as Sjögren's syndrome. Although the T follicular helper (Tfh) cell response has been shown to drive SjD development in a mouse model of experimental Sjögren's syndrome (ESS), the connection between IFN-I and the Tfh cell response remains unclear. As the activation of stimulator of interferon genes (STING) induces IFN-I production, we first demonstrated that mice deficient in STING or IFN-I signaling presented diminished Tfh cells and were completely resistant to ESS development.
View Article and Find Full Text PDFReal-world treatment practices and survival outcomes of patients with de novo metastatic nasopharyngeal carcinoma after chemoimmunotherapy.
Cancer Immunol Immunother
September 2025
Department of Radiation Oncology, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
Objective: To evaluate the real-world treatment practices and survival outcomes of patients with de novo metastatic nasopharyngeal carcinoma (dnMNPC) after the combination of programmed death-1(PD-1) inhibitors with chemotherapy.
Methods: We retrospectively gathered data from patients with dnMNPC who were treated with a combination of chemotherapy and PD-1 inhibitors between August 2019 and August 2023. Kaplan-Meier analysis and Cox proportional hazards regression model were used for statistical analyses.